Researchers find drug that inhibits acute leukemia cell growthApril 27, 2009Pre-clinical study shows 50 percent reduced tumor cell burden SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology (ASPHO). "There is a certain receptor we now know is expressed in acute myeloid leukemia (AML) cells called Tropomyosin Receptor Kinase A (TRKA)," said Mauricio Ghisoli, M.D., fellow at the Children's Cancer Hospital at M. D. Anderson. "When TRKA gets turned on by a nerve growth factor (NGF) ligand, the AML cells start to rapidly grow." Ghisoli and researchers at M. D. Anderson have found that using a TRK inhibitor, AZ23, turns off NGF, which led to a 50 percent reduction of AML cells in mice with no immune system. When studied in mice with an immune system present, researchers found that 60 percent of the mice treated with AZ23 had long-term survival with no presence of leukemia cells. They also found AZ23 to be more effective in human AML cell lines that expressed higher levels of TRKA. This pre-clinical discovery could potentially allow clinicians to decipher which patients may have the best response to the drug in the future, explained Ghisoli. Acute leukemia is the most common cancer in children, according to the American Cancer Society. Acute lymphoblastic leukemia, the more common type, has a cure rate of 80 percent, but children with the rarer type, AML, have only a 50 percent chance of a cure in comparison. "Young patients with acute lymphocytic leukemia have a great chance of being cured using the standard treatments available out there today," said Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator. "However, we have to find alternatives to increase the chance of cure for pediatric patients diagnosed with AML. Understanding how to turn off switches that promote cancer cell production is one way to do this." In pre-clinical tests on solid tumor cell lines, AZ23 was found effective against the tumors. A Phase I clinical trial is planned to open this year for adults with solid tumor cancers. University of Texas M. D. Anderson Cancer Center |
|||||||||||||||||||||
| Related Leukemia Current Events and Leukemia News Articles New research into the mechanisms of gene regulation A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth. UAB Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Drug shows promise in treating dangerous complication of erectile disorder Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Brain tumors in childhood leave a lasting mark on cognition, life status Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems. More Leukemia Current Events and Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||